Rabobank, DLL, and the European Investment Bank are partnering to increase access to finance for SMEs and mid-caps with a particular emphasis on sustainability and bioeconomy sectors, including agriculture.
The European Investment Bank (EIB) and Dutch clinical-stage biotechnology company Leyden Laboratories B.V. have signed a €20 million financing deal to advance development of the Company’s broadly-protective antibodies to defend against seasonal and pandemic viral infections. Leyden Labs’ lead program is a pan-influenza nasal spray currently in clinical development (PanFlu), which has the potential to provide first-in-class influenza protection and meaningfully reduce the burden of influenza infection, including in infection from Avian Flu (H5).
EIB Group and ABN AMRO sign synthetic securitisation agreement, enabling €1.2 billion in new lending for Dutch businesses, part of the new funding is earmarked for sustainable SMEs.